AN2 Therapeutics (ANTX) Non-Current Assets (2021 - 2025)

AN2 Therapeutics (ANTX) has 5 years of Non-Current Assets data on file, last reported at $2.0 million in Q4 2025.

• On a quarterly basis, Non-Current Assets fell 65.44% year-over-year to $2.0 million in Q4 2025; TTM through Mar 2026 was $13.5 million, a 27.44% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, down 65.44% from the prior year.
• Non-Current Assets for Q4 2025 stood at $2.0 million, down from $3.2 million in the prior quarter.
• Over the last five years, Non-Current Assets for ANTX reached as high as $28.2 million in Q4 2023 and fell as low as $720000.0 in Q1 2022.
• Historically, Non-Current Assets has averaged $6.9 million across 5 years, with a median of $3.6 million in 2022.
• Across the five-year window, Non-Current Assets surged 910.29% in 2023 and tumbled 79.37% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $5.2 million in 2021, then decreased by 24.4% to $3.9 million in 2022, then surged by 616.86% to $28.2 million in 2023, then tumbled by 79.37% to $5.8 million in 2024, then tumbled by 65.44% to $2.0 million in 2025.
• Per Business Quant data, the three most recent Non-Current Assets figures were $2.0 million in Q4 2025, $3.2 million in Q3 2025, and $8.3 million in Q2 2025.